STAAR Surgical (NASDAQ:STAA) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund decreased its stake in shares of STAAR Surgical (NASDAQ:STAA) by 43.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 36,456 shares of the medical instruments supplier’s stock after selling 28,003 shares during the period. New York State Common Retirement Fund owned 0.07% of STAAR Surgical worth $886,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Van ECK Associates Corp grew its holdings in STAAR Surgical by 12.7% during the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares in the last quarter. Creative Planning boosted its position in STAAR Surgical by 8.0% in the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 408 shares during the last quarter. LMR Partners LLP grew its stake in shares of STAAR Surgical by 2.2% during the third quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier’s stock valued at $1,290,000 after acquiring an additional 743 shares in the last quarter. Quarry LP acquired a new stake in shares of STAAR Surgical during the third quarter valued at about $50,000. Finally, Kornitzer Capital Management Inc. KS increased its position in shares of STAAR Surgical by 1.2% during the third quarter. Kornitzer Capital Management Inc. KS now owns 164,625 shares of the medical instruments supplier’s stock worth $6,116,000 after acquiring an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analyst Ratings Changes

STAA has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. BTIG Research cut STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Stifel Nicolaus cut their price target on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Canaccord Genuity Group cut their price target on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Finally, William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $26.86.

STAAR Surgical Stock Down 5.9 %

Shares of STAAR Surgical stock opened at $16.47 on Tuesday. The firm has a market cap of $812.38 million, a P/E ratio of -40.17 and a beta of 0.62. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68. The business has a 50-day moving average price of $21.55 and a 200 day moving average price of $27.18.

Insider Activity at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. bought 8,221 shares of the stock in a transaction dated Thursday, January 16th. The stock was bought at an average cost of $21.50 per share, with a total value of $176,751.50. Following the completion of the acquisition, the insider now owns 10,878,007 shares of the company’s stock, valued at $233,877,150.50. This trade represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought a total of 910,843 shares of company stock valued at $15,509,972 over the last three months. 1.00% of the stock is owned by insiders.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.